Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara

Marín-López, Alejandro; Barreiro-Piñeiro, Natalia; Utrilla-Trigo, Sergio; Barriales, Diego; Benavente, Javier; Nogales, Aitor; Martı́nez-Costas, José; Ortego, Javier; Calvo-Pinilla, Eva

doi:10.1016/j.vaccine.2019.10.087

Cited by 11 publications

(8 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indirect enzyme-linked immunosorbent assays (ELISA) were used to determine specific VP2 and NS1 antibody levels before infection 66,67 . MaxiSorp plates (Nunc, USA) were coated with 300 ng/well of purified recombinant VP2 or NS1 protein expressed in Bac-To-Bac Baculovirus expression System (Invitrogen) 20,66 .…”

Section: Enzyme-linked Immunosorbent Assaysmentioning

confidence: 99%

A protective bivalent vaccine against Rift Valley fever and bluetongue

et al. 2020

Self Cite

View full text Add to dashboard Cite

Rift Valley fever (RVF) and bluetongue (BT) are two important ruminant diseases transmitted by arthropods. Both viruses have shown important geographic spread leading to endemicity of BT virus (BTV) in Africa and Europe. In this work, we report a dual vaccine that simultaneously induces protective immune responses against BTV and RVFV based on modified vaccinia Ankara virus (MVA) expressing BTV proteins VP2, NS1, or a truncated form of NS1 (NS1-Nt), and RVFV Gn and Gc glycoproteins. IFNAR (−/−) mice immunized with two doses of MVA-GnGc-VP2 developed a significant neutralizing antibody response against BTV-4 and RVFV. Furthermore, the homologous prime-boost immunization with MVA-GnGc-NS1 or MVA-GnGc-NS1-Nt triggered neutralizing antibodies against RVFV and NS1-specific cytotoxic CD8+ T cells in mice. Moreover, all mice immunized with MVA-GnGc-NS1 or MVA-GnGc-NS1-Nt remained healthy after lethal challenge with RVFV or BTV-4. The homologous prime-boost vaccination with MVA-GnGc-NS1, which was the best immunization strategy observed in mice, was assayed in sheep. Clinical signs and viremia were absent or highly reduced in vaccinated sheep after challenge with BTV-4 or RVFV. These results indicate that MVA-GnGc-NS1 vaccination elicits immune protection against RVFV and BTV in sheep.

show abstract

Section: Enzyme-linked Immunosorbent Assaysmentioning

confidence: 99%

A protective bivalent vaccine against Rift Valley fever and bluetongue

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Expansion of CD8+ T cells has been observed in BTV- and AHSV-infected and vaccinated hosts [ 121 , 122 ]. Indeed, infected animals can mount CD8+ T-cell-mediated protective responses against homologous and heterologous non-related serotypes of BTV and AHSV—with highly conserved proteins VP7, NS1 and NS2 as potential targets—in the absence of neutralizing antibodies (Nabs) [ 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 ]. In this regard, DC cross-priming of cytotoxic T cells plays a critical role after VLP vaccination [ 132 ].…”

Section: Interaction Of Nano- or Microcarriers With The Immune Systemmentioning

confidence: 99%

“…Much better, heterologous combination with MVA expressing NS1 conferred sterile protection in IFNAR(-/-) mice. Despite AHSV-9 not being lethal in IFNAR(-/-) mice, the heterologous strategy also prevented mice from developing viraemia and weight loss, indicating the multiserotype protective potential of NS1 [ 128 ]. Certainly, further research should be carried out on AHSV natural hosts to confirm the results observed in the mouse model.…”

Section: African Horse Sickness Virus (Ahsv)mentioning

confidence: 99%

Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance

et al. 2022

Self Cite

View full text Add to dashboard Cite

Bluetongue virus (BTV) and African horse sickness virus (AHSV) are widespread arboviruses that cause important economic losses in the livestock and equine industries, respectively. In addition to these, another arthropod-transmitted orbivirus known as epizootic hemorrhagic disease virus (EHDV) entails a major threat as there is a conducive landscape that nurtures its emergence in non-endemic countries. To date, only vaccinations with live attenuated or inactivated vaccines permit the control of these three viral diseases, although important drawbacks, e.g., low safety profile and effectiveness, and lack of DIVA (differentiation of infected from vaccinated animals) properties, constrain their usage as prophylactic measures. Moreover, a substantial number of serotypes of BTV, AHSV and EHDV have been described, with poor induction of cross-protective immune responses among serotypes. In the context of next-generation vaccine development, antigen delivery systems based on nano- or microparticles have gathered significant attention during the last few decades. A diversity of technologies, such as virus-like particles or self-assembled protein complexes, have been implemented for vaccine design against these viruses. In this work, we offer a comprehensive review of the nano- and microparticulated vaccine candidates against these three relevant orbiviruses. Additionally, we also review an innovative technology for antigen delivery based on the avian reovirus nonstructural protein muNS and we explore the prospective functionality of the nonstructural protein NS1 nanotubules as a BTV-based delivery platform.

show abstract

“…Of concern, LAVs are associated with reversion to virulence, vector’s transmission, absence of DIVA (Differentiating Infected from Vaccinated Animals) capacity, teratogenicity, and gene reassortment that lead to the establishment of new genetic variants [ 3 , 14 , 15 , 16 , 17 , 18 ]. To address the need for safe and more effective vaccines, several candidates have been evaluated including subunit vaccines, virus like particles (VLPs), avian reovirus muNS protein microspheres (MS), recombinant poxviruses and reverse genetic approaches [ 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 •• , 29 •• , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 • ] ( Table 1 ).…”

Section: New Approaches In Vaccine Generation Against Ahsvmentioning

confidence: 99%

“…In a more recent work, NS1 from AHSV-4 was incorporated into avian reovirus muNS protein microspheres (MS-NS1) and combined to MVA-NS1 to test protective immunity in mice. This combinatorial immunization afforded sterilizing protection after infection with heterologous serotype 9 and it would be a promising universal vaccine against AHSV [ 37 • ].…”

Section: New Approaches In Vaccine Generation Against Ahsvmentioning

confidence: 99%

Reverse genetics approaches: a novel strategy for African horse sickness virus vaccine design

Calvo-Pinilla

Marín-López

Utrilla-Trigo

et al. 2020

Current Opinion in Virology

Self Cite

View full text Add to dashboard Cite

African horse sickness (AHS) is a devastating disease caused by African horse sickness virus (AHSV) and transmitted by arthropods between its equine hosts. AHSV is endemic in sub-Saharan Africa, where polyvalent live attenuated vaccine is in use even though it is associated with safety risks. This review article summarizes and compares new strategies to generate safe and effective AHSV vaccines based on protein, virus like particles, viral vectors and reverse genetics technology. Manipulating the AHSV genome to generate synthetic viruses by means of reverse genetic systems has led to the generation of potential safe vaccine candidates that are under investigation.

show abstract

Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara

Cited by 11 publications

References 35 publications

A protective bivalent vaccine against Rift Valley fever and bluetongue

A protective bivalent vaccine against Rift Valley fever and bluetongue

Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance

Reverse genetics approaches: a novel strategy for African horse sickness virus vaccine design

Contact Info

Product

Resources

About